Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16.

H Yasui,Y Okita,M Nakamura,T Sagawa,T Watanabe,K Kataoka,D Manaka, K Shiraishi,N Akazawa,T Okuno, T Shimura,M Shiozawa,Y Sunakawa,H Ota,M Kotaka, H Okuyama, M Takeuchi,W Ichikawa,M Fujii,A Tsuji

ESMO open（2023）

Cited 0|Views20
No score
Abstract
Our study demonstrated prospectively that RAM plus FOLFIRI is an effective second-line treatment after anti-EGFR antibody-containing first-line therapy in RAS wild-type and left-sided mCRC. Furthermore, the results were similar for patients who were previously treated with triplet regimen.
More
Translated text
Key words
metastatic colorectal cancer,colorectal cancer,antibody,folfiri,second-line,wild-type,anti-egfr
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined